All Experimentica sites are now CIR-accredited
Experimentica’s sites have gained CIR accreditation for 2026-2028, enabling eligible French companies to benefit from CIR-covered preclinical ophthalmic research services.
Learn moreExperimentica’s sites have gained CIR accreditation for 2026-2028, enabling eligible French companies to benefit from CIR-covered preclinical ophthalmic research services.
Learn moreResearchers at Experimentica have demonstrated that human induced pluripotent stem cell-derived retinal pigment epithelium (hiPSC-RPE) cells provide a highly relevant in vitro model for studying oxidative stress-related retinal diseases, including age-related macular degeneration (AMD). The study showed that these cells closely resemble native human RPE tissue both morphologically and functionally, making them a valuable platform for preclinical research and drug development.
Learn moreHeading to Boston or based in the area? Let’s connect! Whether you’re attending LSX or are simply in the Boston area, our Business Development team would be happy to meet and discuss your ophthalmic drug development needs.
Learn moreExperimentica has appointed Dr. Marc Cerrada-Gimenez as Director, In Vivo GLP Operations, supporting the expansion of its GLP safety and toxicology capabilities in Kuopio, Finland.
Learn moreIn 2026, we will be attending a range of key events across the globe - and we invite you to meet us in person! Join us to discuss ideas, explore opportunities, and see how we can support you and your team in ocular drug development.
Learn moreExperimentica strengthens its position as a leading global ophthalmic CRO by investing in a new GLP‑compliant facility, enabling comprehensive GLP safety and toxicology studies for innovative ocular therapies.
Learn moreExperimentica Ltd., a trusted partner in preclinical drug development for ocular diseases, is pleased to announce the appointment of Teija Parkkari as Director of Business Development, effective April 13, 2026.
Learn moreExperimentica utilizes a validated mouse model of dry eye disease. Dry eye disease-like pathology is induced using transdermal scopolamine patches in combination with desiccating environmental stress. The induced pathology is characterized using corneal fluorescein staining, tear volume measurements, and histology for lacrimal gland infiltration, goblet cell loss, and corneal abnormalities.
Learn moreExperimentica Ltd., a global contract research organization (CRO) dedicated to preclinical models of ophthalmic diseases, announces a significant expansion of its Kuopio site in Finland.
Learn moreA brief overview of streptozotocin-induced diabetic retinopathy in rodents, highlighting strain-specific differences, quantitative assessment of retinal vascular leakage, identification of the most consistent and reliable readout, and animal welfare considerations.
Learn moreCopyright: Experimentica Ltd. 2026